COLL · Collegium Pharmaceutical, Inc.
$22.96
-2.30% last session
End-of-day data · close of 2026-10-23
Market cap
$1B
Enterprise value
$2B
Trailing P/E
18.1
Forward P/E
3.2
Dividend yield
0.0%
Beta
0.73
Avg volume
1M
Employees
0K
Daily Change %
-2.30%
5 Days Change
-0.22%
10 Days Change
2.00%
30 Days Change
1.41%
60 Days Change
-16.42%
Month to Day Change
5.13%
Year to Day Change
-50.41%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — COLL
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-23
Latest call per bank · past 12 months
Barclays
Overweight$48.00
+109.1% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-23 | Oppenheimer | Initiates | Outperform | $0.00 → $50.00 |
| 2026-09-09 | Truist Securities | Maintains | Buy | $58.00 → $49.00 |
| 2026-09-09 | Leerink Partners | Initiates | Outperform | $0.00 → $45.00 |
| 2026-08-19 | Barclays | Maintains | Overweight | $56.00 → $48.00 |
| 2026-08-07 | Piper Sandler | Reiterates | Neutral | $45.00 → $43.00 |
| 2026-08-06 | Needham | Maintains | Buy | $56.00 → $46.00 |
| 2026-03-20 | HC Wainwright & Co. | Reiterates | Buy | $60.00 |
| 2026-03-19 | Needham | Reiterates | Buy | $54.00 → $56.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 49 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 3.5% below the 50-day MA ($23.78).
- bearish: Price vs 200-day MA: Trading 32.1% below the 200-day MA ($33.83).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.28) — short-term momentum is improving.
- bearish: 52-week range: Price is within 10% of the 52-week low ($21.53).
COLL Price Chart
Loading chart for COLL…
Fundamentals
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$65B 30.6% YTD
TEVA
Teva Pharmaceutical Industries
$46B 28.8% YTD
HLN
Haleon plc
$45B 4.6% YTD
ZTS
Zoetis Inc.
$33B -33.8% YTD
UTHR
United Therapeutics Corporation
$25B 20.0% YTD
VTRS
Viatris Inc.
$21B 51.9% YTD
NBIX
Neurocrine Biosciences, Inc.
$15B 1.0% YTD
ELAN
Elanco Animal Health Incorporat
$11B 0.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.